Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza białaczki limfocytowej (CLL)
- •Nowe przepisanie leku acalabrutinib w ostatnie cztery tygodnie przed badaniem
- •Lek podawany samodzielnie, bez jednoczesnego stosowania innych leków przeciw białaczce
- •Pacjenci wcześniej nieleczeni lub leczeni wcześniej nieskutecznie
✗ Disqualifies
- •Wcześniejsze leczenie inhibitorami BTK
- •Uczestnictwo w innych badaniach klinicznych
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Locations (3)
Research Site
Grodno, Belarus
Research Site
Homyel, Belarus
Research Site
Minsk, Belarus
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.